Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 5 months ago
Share
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
357 patients around the world
Available in
United States, Brazil, Spain
GlaxoSmithKline
357
Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
See details
Contact us
Contact us
Study
DREAMM 8
Sponsor
GlaxoSmithKline
Study type
Interventional
Conditions
Multiple myeloma
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT04484623
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent